New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura

The Lancet

Volumn 373, Issue 9674, 2009, Pages 1562-1569

  Nurden, Alan T ^a   Viallard, Jean François ^b   Nurden, Paquita ^a  

^a Ctr Geriatrie Ctr Hosp Univ B   (France)

^b HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AKR 501; AUTOANTIBODY; AZATHIOPRINE; BLOOD CLOTTING FACTOR 7A; CD40 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DANAZOL; DAPSONE; DEXAMETHASONE; ELTROMBOPAG; GAMMA INTERFERON; IMMUNOGLOBULIN G; MEPREDNISONE; MYCOPHENOLIC ACID; NIP 004; NPLATE; PLACEBO; PREDNISOLONE; PREDNISONE; PROTEIN KINASE SYK INHIBITOR; R 406; R 788; RITUXIMAB; ROMIPLOSTIM; TAMATINIB FOSDIUM; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR; UNCLASSIFIED DRUG; VINCA ALKALOID;

ADVERSE DRUG REACTION; BLEEDING; CELL STIMULATION; CHRONIC DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE MARKER; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL DISEASE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE RESPONSE; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA; MEGAKARYOCYTE; NONHUMAN; PRIORITY JOURNAL; REFRACTORY PERIOD; REPEATED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPOIESIS; THROMBOEMBOLISM; THROMBOSIS; TREATMENT FAILURE;

EID: 65349176604     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60255-5     Document Type: Review

References (80)

1. George J.N., Woolf S.H., Raskob G.E., et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 88 (1996) 3-40
2. British Committee for Standards in Haematology General Haematology Task Force Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 120 (2003) 574-596
3. Tarantino M.D., and Bolton-Maggs P.H. Update on the management of immune thrombocytopenic purpura in children. Curr Opin Hematol 14 (2007) 526-534
4. Cines D.B., and McMillan R. Pathogenesis of chronic immune thrombocytopenic purpura. Curr Opin Hematol 14 (2007) 511-514
5. Godeau B., Provan D., and Bussel J. Immune thrombocytopenic purpura in adults. Curr Opin Hematol 14 (2007) 535-556
6. Deutsch V.R., and Tomer A. Megakaryocyte development and platelet production. Br J Haematol 134 (2006) 453-466
7. Junt T., Schulze H., Chen Z., et al. Dynamic visualization of thrombopoiesis within bone marrow. Science 317 (2007) 1767-1770
8. Kaushansky K., and Drachman J.G. The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production. Oncogene 21 (2002) 3359-3367
9. Sungaran R., Markovic B., and Chong B.H. Localization of thrombopoietin mRNA expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. Blood 89 (1997) 101-107
10. Mason K.D., Carpinelli M.R., Fletcher J.I., et al. Programmed anuclear cell death delimits platelet life span. Cell 128 (2007) 1173-1186
11. Ballem P.J., Segel G.M., Stratton J.E., et al. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 80 (1987) 33-40
12. Semple J.W., and Freedman J. Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia. Blood 78 (1991) 2619-2625
13. Yu J., Heck S., Patel V., et al. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood 112 (2008) 1325-1328
14. Olsson B., Andersson P.O., Jernas M., et al. T-cell mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 9 (2003) 1123-1124
15. Chang M., Nakagawa P.A., Williams S.A., et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 102 (2003) 887-895
16. Howerzijl E.J., Blom N.R., Van der Want J.J.L., et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood 103 (2004) 500-506
17. Olsson B., Ridell B., Carlsson L., et al. Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1. Blood 112 (2008) 1078-1084
18. Nurden P., and Nurden A.T. Congenital disorders associated with platelet dysfunctions. Thromb Haemost 99 (2008) 253-263
19. Fogarty P.F., and Segal J.B. The epidemiology of immune thrombocytopenic purpura. Curr Opin Hematol 14 (2007) 515-519
20. Bussel J.B. Novel approaches to refractory immune thrombocytopenic purpura. Blood Rev 16 (2002) 31-36
21. Cooper N., Heddle N.M., De Haas M., et al. Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcγRIIa and FcγRIIIa polymorphisms. Br J Haematol 124 (2004) 511-518
22. Siragam V., Crow A.R., Brinc D., et al. Intravenous immunoglobulin ameliorates ITP via activating Fcγ receptors on dendritic cells. Nat Med 12 (2006) 688-692
23. Anthony R.M., Nimmerjahn F., Ashline D.J., et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320 (2008) 373-376
24. Kojouri K., Vesely S.K., Terrell D.R., and George J.N. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 104 (2004) 2623-2634
25. Kuwana M., Okazaki Y., Kaburaki J., et al. Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura. J Immunol 168 (2002) 3675-3682
26. Stasi R., Evangelista M.L., Stipa E., et al. Idiopathic thrombocytopenic purpura: Current concepts in pathophysiology and management. Thromb Haemost 99 (2008) 4-13
27. Boruchov D.M., Gururangan S., Driscoll M.C., and Bussell J.B. Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood 110 (2007) 3526-3531
28. Emilia G., Morselli M., Luppi M., et al. Long-term salvage therapy with cyclosporin A in refractory immune thrombocytopenic purpura. Blood 99 (2002) 1482-1485
29. Cooper N., Stasi R., Cunningham-Rundles S., et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 125 (2004) 232-239
30. Mueller B.U., Bennett C.M., Feldman H.A., et al. One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab. Pediatr Blood Cancer 52 (2009) 259-262
31. Stasi R., Del Poeta G., Stipa E., et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 110 (2007) 2924-2930
32. Stasi R., Cooper N., Del Poeta G., et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 112 (2008) 1147-1150
33. Kuwana M., Kawakami Y., and Ikeda Y. Suppression of autoreactive T-cell response to glycoprotein IIb-IIIa by blockade of CD40/CD154 interaction: implications for treatment of immune thrombocytopenic purpura. Blood 101 (2003) 621-623
34. Solanilla A., Pasquet J.M., Viallard J.F., et al. Platelet-associated CD154 in immune thrombocytopenic purpura. Blood 105 (2005) 215-218
35. Patel V.L., Schwartz J., and Bussel J.B. The effect of anti-CD40 ligand in immune thrombocytopenic purpura. Br J Haematol 141 (2008) 545-548
36. Kuter D.J. New thrombopoietic growth factors. Blood 109 (2007) 4607-4616
37. Bussel J.B., Cheng G., Saleh M.N., et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 357 (2007) 2237-2247
38. Kuter D.J., Bussel J.B., Lyons R.M., et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 371 (2008) 395-403
39. Bussel J.B., Kuter D.J., Pullarkat V., et al. Safety and efficacy of long-term treatment with rombiplostim in thrombocytopenic patients with chronic ITP. Blood 113 (2009) 2161-2171
40. Godeau B., Porcher R., Fain O., et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood 112 (2008) 999-1004
41. Kuter D.J., and Begley C.G. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 100 (2002) 3457-3469
42. James C., Ugo V., Le Couédic J.-P., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 (2005) 1144-1148
43. Porcelijn L., Folman C.C., Bossers B., et al. The diagnostic value of thrombopoietin level measurements in thrombocytopenia. Thromb Haemost 79 (1998) 1101-1105
44. McIntosh B., and Kaushansky K. Transcriptional regulation of bone marrow thrombopoietin by platelet proteins. Exp Hematol 36 (2008) 799-806
45. Cwirla S.E., Balasubramanian P., Duffin D.J., et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 276 (1997) 1696-1699
46. Deng B., Banu N., Malloy B., et al. An agonist murine monoclonal antibody to the human c-MPL receptor stimulates megakaryocytopoiesis. Blood 92 (1998) 1981-1988
47. Harker L.A., Roskos L.K., Marzec U.M., et al. Effects of megakaryocyte growth and development factor on platelet production, platelet life span and platelet function in healthy human volunteers. Blood 95 (2000) 2514-2522
48. Vadhan-Raj S., Verschraegen C.F., Bueso-Ramos C., et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynaecologic cancer. Ann Intern Med 132 (2000) 364-368
49. Li J., Yang C., Xia Y., et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98 (2001) 3241-3248
50. Kimura T., Kaburaki H., Tsujino T., et al. A non-peptide compound which can mimic the effect of thrombopoietin via c-Mpl. FEBS Lett 428 (1998) 250-254
51. Broudy V.C., and Lin N.L. AMG531 stimulates megakaryocytopoiesis in vitro by binding to Mpl. Cytokine 25 (2004) 52-60
52. Wang B., Nichol J.L., and Sullivan J.T. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 76 (2004) 628-638
53. Erickson-Miller C.L., DeLorme E., Tian S.S., et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol 33 (2005) 85-93
54. Inagaki K., Oda T., Naka Y., et al. Induction of megakaryocytopoiesis and thrombocytopoiesis by JTZ-132, a novel small molecule with thrombopoietin mimetic activities. Blood 104 (2004) 58-64
55. Orita T., Tsunoda H., Yabuta N., et al. A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor. Blood 105 (2005) 562-566
56. Frederickson S., Renshaw M.W., Lin B., et al. A rationally designed agonist antibody fragment that functionally mimics thrombopoietin. Proc Natl Acad Sci USA 103 (2006) 14307-14312
57. Jenkins J.M., Williams D., Deng Y., et al. Phase I clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 109 (2007) 4739-4741
58. Bussel J.B., Cheng G., Saleh M.N., et al. Long-term safety and efficacy of oral eltrombopag for the treatment of idiopathic thrombocytopenic purpura (ITP). Haematologica 93 suppl (2008) 379 (abstr).
59. Bussel J.B., Cheng G., Saleh M.N., et al. Oral elthrombopag spares corticosteroids and reduces bleeding in patients with idiopathic thrombocytopenic purpura (ITP). 13th congress of the European Haematology Association, June 12-15, 2008, Copenhagen, Denmark. Abstract 0306. Haematologica 93 suppl (2008) 125 (abstr).
60. Kumagai Y., Fujita T., Ozaki M., et al. Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody in healthy Japanese subjects: a randomized, placebo-controlled study. J Clin Pharmacol 47 (2007) 1489-1497
61. Newland A., Caulier M.T., Lappers-Klunne M., et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol 135 (2006) 547-553
62. Bussel J.B., Kuter D.J., George J.N., et al. AMG531, a thrombopoietin-stimulating protein, for chronic ITP. New Engl J Med 355 (2006) 1672-1681
63. Despujol C.-D., Michel M., Khellaf M., et al. Antiphospholipid antibodies in adults with immune thrombocytopenic purpura. Br J Haematol 142 (2008) 638-643
64. Nakamura T., Miyakawa Y., Miyamura A., et al. A novel nonpeptidyl human c-MPL activator stimulates human megakaryopoiesis and thrombopoiesis. Blood 107 (2006) 4300-4307
65. Yamane A., Nakamura T., Suzuki H., et al. Interferon alpha 2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes. Blood 112 (2008) 542-550
66. Fukushima-Shintani M., Suzuki K.I., Iwatsuki Y., et al. AKR-501 (YM477) in combination with thrombopoietin enhances human megakaryocytopoiesis. Exp Hematol 36 (2008) 1337-1342
67. Desjardins R.E., Tempel D.L., Lucek R., and Kuter D.J. Single and multiple oral doses of AKR-501 (YM477) increases the platelet count in healthy volunteers. J Support Oncol 5 suppl 2 (2007) 68-69
68. Nogami W., Yoshida H., Koizumi K., et al. The effect of a novel, small nonpeptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis. Haematologica 93 (2008) 1495-1504
69. Braselmann S., Taylor V., Zhao H., et al. R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther 319 (2006) 998-1008
70. Bahjat F.R., Pine P.R., Reitsma A., et al. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum 58 (2008) 1433-1444
71. Podolanczuk A., Lazarus A.H., Crow A.R., et al. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura (ITP) by an inhibitor of Syk. Blood (2008) 10.1182/blood-2008-07-166439 published online Dec 18.
72. McHutchison J.G., Dusheiko G., Shiffman M.L., et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 357 (2007) 2227-2236
73. Tiu R.V., and Sekeres M.A. The role of AMG-531 in the treatment of thrombocytopenia in idiopathic thrombocytopenic purpura and myelodysplastic syndromes. Expert Opin Biol Ther 8 (2008) 1021-1030
74. Kobos R., and Bussel J.B. Overview of thrombopoietic agents in the treatment of thrombocytopenia. Clin Lymphoma Myeloma 8 (2008) 33-40
75. Samoylenko A., Byts N., Rajalingam K., et al. Thrombopoietin inhibits nerve growth factor-induced neuronal differentiation and ERK signalling. Cell Signal 20 (2008) 154-162
76. Baker J.E., Su J., Hsu A., et al. Human thrombopoietin reduces myocardial infarct size, apoptosis, and stunning following ischaemia/reperfusion in rats. Cardiovasc Res 77 (2008) 44-53
77. George J.N. Management of patients with refractory immune thrombocytopenic purpura. J Thromb Haemost 4 (2006) 1664-1672
78. George J.N., Mathias S.D., Go R.S., et al. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol 144 (2009) 409-415
79. Stasi R., Sarpatwari A., Segal J.B., et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood 113 (2009) 1231-1240
80. Rioux J.D., and Abbas A.K. Paths to understanding the genetic basis of autoimmune disease. Nature 435 (2005) 584-589